Alnylam Pharmaceuticals, Inc. (ALNY) Earns Sell Rating from Analysts at Janney Montgomery Scott
Analysts at Janney Montgomery Scott initiated coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued on Friday, June 2nd. The firm set a “sell” rating and a $67.00 price target on the biopharmaceutical company’s stock. Janney Montgomery Scott’s target price points to a potential downside of 20.73% from the company’s previous close.
Several other brokerages have also recently weighed in on ALNY. Vetr cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. Piper Jaffray Companies set a $118.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Chardan Capital lowered their price target on Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, May 15th. Ladenburg Thalmann Financial Services set a $80.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. Finally, ValuEngine lowered Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 27th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $71.82.
Shares of Alnylam Pharmaceuticals (ALNY) opened at 84.52 on Friday. The firm’s market capitalization is $7.28 billion. The stock’s 50 day moving average price is $67.47 and its 200-day moving average price is $51.64. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $84.18.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. During the same quarter in the previous year, the company posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.30) earnings per share for the current year.
In other news, EVP Akshay Vaishnaw sold 11,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total value of $825,000.00. Following the sale, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at $1,597,275. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sanofi bought 297,501 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 31st. The stock was purchased at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 64,125 shares of company stock worth $4,325,000. Insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $4,632,000. Aviva PLC raised its position in Alnylam Pharmaceuticals by 6.2% in the fourth quarter. Aviva PLC now owns 48,022 shares of the biopharmaceutical company’s stock valued at $1,797,000 after buying an additional 2,793 shares in the last quarter. Hemenway Trust Co LLC raised its position in Alnylam Pharmaceuticals by 25.2% in the fourth quarter. Hemenway Trust Co LLC now owns 16,773 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 3,373 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. Finally, State Street Corp raised its position in shares of Alnylam Pharmaceuticals by 1.2% in the fourth quarter. State Street Corp now owns 2,361,998 shares of the biopharmaceutical company’s stock valued at $88,430,000 after buying an additional 28,822 shares during the period. Institutional investors own 90.04% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.